105 related articles for article (PubMed ID: 11425972)
21. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
22. Differentiating benign and malignant pulmonary lesions with FDG-PET.
Yang SN; Liang JA; Lin FJ; Kwan AS; Kao CH; Shen YY
Anticancer Res; 2001; 21(6A):4153-7. PubMed ID: 11911310
[TBL] [Abstract][Full Text] [Related]
23. Gliomatosis cerebri evaluated by 18Falpha-methyl tyrosine positron-emission tomography.
Sato N; Inoue T; Tomiyoshi K; Aoki J; Oriuchi N; Takahashi A; Otani T; Kurihara H; Sasaki T; Endo K
Neuroradiology; 2003 Oct; 45(10):700-7. PubMed ID: 13680026
[TBL] [Abstract][Full Text] [Related]
24. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
25. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
[TBL] [Abstract][Full Text] [Related]
26. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
27. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis.
Dewan NA; Reeb SD; Gupta NC; Gobar LS; Scott WJ
Chest; 1995 Aug; 108(2):441-6. PubMed ID: 7634881
[TBL] [Abstract][Full Text] [Related]
28. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
29. Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose.
Woesler B; Kuwert T; Morgenroth C; Matheja P; Palkovic S; Schäfers M; Vollet B; Schäfers K; Lerch H; Brandau W; Samnick S; Wassmann H; Schober O
Eur J Nucl Med; 1997 Apr; 24(4):428-34. PubMed ID: 9096095
[TBL] [Abstract][Full Text] [Related]
30. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
31. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging?
Hoegerle S; Juengling F; Otte A; Altehoefer C; Moser EA; Nitzsche EU
Radiology; 1998 Oct; 209(1):253-8. PubMed ID: 9769840
[TBL] [Abstract][Full Text] [Related]
32. PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results.
Pauleit D; Stoffels G; Schaden W; Hamacher K; Bauer D; Tellmann L; Herzog H; Bröer S; Coenen HH; Langen KJ
J Nucl Med; 2005 Mar; 46(3):411-6. PubMed ID: 15750152
[TBL] [Abstract][Full Text] [Related]
33. FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders.
Delbeke D; Patton JA; Martin WH; Sandler MP
J Nucl Med; 1999 Jan; 40(1):110-7. PubMed ID: 9935066
[TBL] [Abstract][Full Text] [Related]
34. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps.
Delbeke D; Martin WH; Patton JA; Sandler MP
Radiology; 2001 Jan; 218(1):163-71. PubMed ID: 11152796
[TBL] [Abstract][Full Text] [Related]
35. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
36. Oncological diagnosis using positron coincidence gamma camera with fluorodeoxyglucose in comparison with dedicated PET.
Zhang H; Tian M; Oriuchi N; Higuchi T; Tanada S; Endo K
Br J Radiol; 2002 May; 75(893):409-16. PubMed ID: 12036833
[TBL] [Abstract][Full Text] [Related]
37. [123I-alpha-methyltyrosine scintigraphy in malignant melanoma].
Steinert H; Böni R; Huch-Böni RA; Capaul R; von Schulthess GK; Westera G
Nuklearmedizin; 1997 Mar; 36(2):36-41. PubMed ID: 9148271
[TBL] [Abstract][Full Text] [Related]
38. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
[TBL] [Abstract][Full Text] [Related]
39. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
40. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
Steinert HC; Huch Böni RA; Buck A; Böni R; Berthold T; Marincek B; Burg G; von Schulthess GK
Radiology; 1995 Jun; 195(3):705-9. PubMed ID: 7753998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
